AARTIDRUGS:NSE-Aarti Drugs Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 771.30

Change

-2,167.10 (-73.75)%

Market Cap

INR 17.98B

Volume

0.33M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. It offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment. The company also provides pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, raloxifene, and zolpidem; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate. In addition, its products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Additionally, the company offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is headquartered in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-30 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-5.70 (-1.13%)

INR1,214.42B 160.86 32.48
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+103.60 (+2.04%)

INR872.17B 44.75 26.36
DIVISLAB:NSE Divi's Laboratories Limited

-13.95 (-0.46%)

INR814.66B 50.23 34.27
AUROPHARMA:NSE Aurobindo Pharma Limited

-0.05 (-0.01%)

INR471.77B 15.36 9.59
LUPIN:NSE Lupin Limited

+9.25 (+0.93%)

INR455.85B 49.28 27.33
CADILAHC:NSE Cadila Healthcare Limited

+7.25 (+1.87%)

INR396.91B 29.06 16.74
ALKEM:NSE Alkem Laboratories Limited

+2.50 (+0.09%)

INR334.16B 24.10 18.33
IPCALAB:NSE Ipca Laboratories Limited

+55.60 (+2.63%)

INR267.61B 28.38 19.52
APLLTD:NSE Alembic Pharmaceuticals Limite..

-12.10 (-1.27%)

INR186.73B 17.42 14.41
NATCOPHARM:NSE NATCO Pharma Limited

-5.45 (-0.57%)

INR174.17B 36.73 24.67

ETFs Containing AARTIDRUGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.31% 32% F 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.31% 32% F 78% C+
Trailing 12 Months  
Capital Gain 69.29% 50% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.29% 50% F 88% B+
Trailing 5 Years  
Capital Gain 27.15% 52% F 66% D
Dividend Return 1.61% 41% F 16% F
Total Return 28.76% 52% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 20.48% N/A N/A 80% B-
Dividend Return 0.25% N/A N/A 20% F
Total Return 20.73% N/A N/A 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 78.17% N/A N/A 13% F
Risk Adjusted Return 26.53% N/A N/A 68% D+
Market Capitalization 17.98B 50% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.16 34% F 26% F
Price/Book Ratio 10.07 7% F 4% F
Price / Cash Flow Ratio 7.17 73% C 38% F
EV/EBITDA 19.97 27% F 25% F
Management Effectiveness  
Return on Equity 23.65% 89% B+ 91% A-
Return on Invested Capital 16.60% 80% B- 87% B+
Return on Assets 8.76% 77% C+ 88% B+
Debt to Equity Ratio 27.63% 21% F 38% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.99 39% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.